192 related articles for article (PubMed ID: 34790350)
1. Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report.
Ito F; Sato T; Emoto K; Kaizuka N; Yagi K; Watanabe R; Hashiguchi MH; Ninomiya H; Ikematsu Y; Tanaka K; Domoto H; Shiomi T
Mol Clin Oncol; 2021 Dec; 15(6):261. PubMed ID: 34790350
[TBL] [Abstract][Full Text] [Related]
2. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma.
Zhu Y; Li S; Wang H; Ren W; Chi K; Wu J; Mao L; Huang X; Zhuo M; Lin D
J Clin Pathol; 2023 Sep; ():. PubMed ID: 37775262
[TBL] [Abstract][Full Text] [Related]
5. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
[TBL] [Abstract][Full Text] [Related]
7. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
[TBL] [Abstract][Full Text] [Related]
8. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
[TBL] [Abstract][Full Text] [Related]
9. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
Kim G; Kim M; Nam EJ; Lee JY; Park E
Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity.
Qi J; Zhang J; Liu N; Zhao L; Xu B
Front Oncol; 2022; 12():779276. PubMed ID: 35311069
[TBL] [Abstract][Full Text] [Related]
11. Dynamic transition of molecular subtypes in relapsed small cell lung cancer treated with multimodal therapy: A case report.
Yasuda K; Haruki T; Miyamoto T; Oshima Y; Matsui S; Kubouchi Y; Nakamura H
Thorac Cancer; 2023 Jul; 14(20):2001-2004. PubMed ID: 37253435
[TBL] [Abstract][Full Text] [Related]
12. Molecular features and evolutionary trajectory of ASCL1
Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z
Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary Neuroendocrine Cells and Small Cell Lung Carcinoma: Immunohistochemical Study Focusing on Mechanisms of Neuroendocrine Differentiation.
Ito T; Kudoh S; Fujino K; Sanada M; Tenjin Y; Saito H; Nakaishi-Fukuchi Y; Kameyama H; Ichimura T; Udaka N; Kudo N; Matsuo A; Sato Y
Acta Histochem Cytochem; 2022 Jun; 55(3):75-83. PubMed ID: 35821751
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
Kawai H; Matsuoka R; Ito T; Matsubara D
Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
[TBL] [Abstract][Full Text] [Related]
16. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
Hwang S; Hong TH; Kim HK; Choi YS; Zo JI; Shim YM; Han J; Chan Ahn Y; Pyo H; Noh JM; Lee HY; Kim HJ; Park S; Ahn MJ; Park K; Lee SH; Choi YL; Kim J
Mod Pathol; 2023 Jul; 36(7):100184. PubMed ID: 37054974
[TBL] [Abstract][Full Text] [Related]
17. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
[TBL] [Abstract][Full Text] [Related]
18. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
[TBL] [Abstract][Full Text] [Related]
19. Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy.
Chen HZ; Bonneville R; Paruchuri A; Reeser JW; Wing MR; Samorodnitsky E; Krook MA; Smith AM; Dao T; Miya J; Wang W; Yu L; Freud AG; Allenby P; Cole S; Otterson G; Shields P; Carbone DP; Roychowdhury S
JTO Clin Res Rep; 2021 Apr; 2(4):100164. PubMed ID: 34590014
[TBL] [Abstract][Full Text] [Related]
20. Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection?
Popper H; Brcic L; Eidenhammer S
Transl Lung Cancer Res; 2023 Dec; 12(12):2412-2426. PubMed ID: 38205203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]